ArticleDiscover oncology2025
Identification of circulating tumor cells marker genes as prognostic signature in triple-negative breast cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundBreast cancer represents a significant contributor to cancer-related mortality among women worldwide, with triple-negative breast cancer (TNBC) often exhibiting more aggressive clinical features and a heightened lethality rate. The emergence of malignant progression, along with issues of drug resistance, poses substantial challenges in the clinical management of this disease.
methodsThe analysis of gene expression profiles at the single-cell level was conducted on circulating tumor cells (CTCs) obtained from TNBC patients, with the objective of identifying specific marker genes associated with CTCs. The TCGA database served as the training cohort for the development of a prognostic CTCs signature model, while the METABRIC dataset was utilized as the validation cohort to assess the robustness of the CTCs signature model. Furthermore, we investigated the differences in prognosis, immune scores, tumor mutational burden, and responses to immunotherapy and chemotherapy across various risk groups established based on the CTCs signature model. Colony formation and transwell assays were conducted to assess the influence of CTCs signature genes on cellular proliferation and invasive capabilities.
resultsSeven marker genes associated with CTCs (BLOC1S3, FOXD2, GZMB, KCNJ13, NTRK3, SOAT2, and ZNF589) were identified and incorporated into a CTCs signature model. The risk score derived from this model stratified TNBC patients into high-risk and low-risk groups. Notably, the overall survival (OS) rate for the low-risk group was significantly higher than that of the high-risk group. Furthermore, the low-risk cohort exhibited more favorable prognostic outcomes and demonstrated heightened sensitivity to both immunotherapy and chemotherapy. Finally, knockdown experiments conducted in TNBC cell lines demonstrated that CTCs signature genes play a crucial role in the regulation of cellular proliferation and invasion.
conclusionThe CTCs signature model offers novel insights into the prognostic significance of CTC marker genes in TNBC. This understanding may serve as a valuable reference for predicting responses to immunotherapy and chemotherapy, as well as for revealing the molecular mechanisms and therapeutic targets of TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.